Data from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Data to be presented include analyses of longterm efficacy and safety of ozanimod in adults with relapsing forms of multiple sclerosis and effects on biomarkers of disease activity Celgene Corporation NASDAQCELG today announced it will present 13 scientifi...